BDNF, Biomarker, Rehabilitation, Stroke
Conditions
Brief summary
This study aims to develop the quantitative biomarker to establish the individualized strategy in stroke rehabilitation. Brain-derived neurotrophic factor (BDNF) acts on certain neurons of the central nervous system (CNS) helping to support the survival of existing neurons, and encourage the growth and differentiation of new neurons and synapses. BDNF in CNS can be assessed by analysing serum BDNF. The final objective of this study is to demonstrate a role of biomarker of BDNF in stroke rehabilitation to establish the individualized strategy.
Detailed description
Serum BDNF, proBDNF and MMP-9 in all participants will be measured before and after the comprehensive inpatient rehabilitation during subacute stroke phase. At 3 months after stroke onset, serum BDNF, proBDNF and MMP-9 will also be measured. In addition, motor impairment with Fugl-Meyer assessement will be assessed at same time points with serum analysis. We will compare potential serum biomarkers with motor impairment in stroke patients
Interventions
comprehensive inpatient rehabilitation for 2 weeks
Sponsors
Samsung Medical Center
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* unilateral stroke patients * admission to the rehabilitation department before 1 month after stroke onset * mild to severe motor impairment at time of transferring to the rehabilitation department
Exclusion criteria
* Progressive or unstable stroke * Pre-existing and active major neurological disease * Pre-existing and active major psychiatric disease * Advanced liver, kidney, cardiac, or pulmonary disease * A terminal medical diagnosis consistent with survival \< 1 year) * Pregnant or lactating woman
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum BDNF | At 2 weeks after the comprehensive inpatient rehabilitation | serum BDNF level |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum proBDNF | At 2 weeks after the comprehensive inpatient rehabilitation | Serum proBDNF level |
| MMP-9 | At 2 weeks after the comprehensive inpatient rehabilitation | MMP-9 level |
Countries
South Korea
Outcome results
None listed